Farnesyltransferase and geranylgeranyltransferase I inhibitors in cancer therapy: Important mechanistic and bench to bedside issues

Expert Opinion on Investigational Drugs

Volumn 9, Issue 12, 2000, Pages 2767-2782

  Sebti, S M ^a   Hamilton, A D ^a  

^a H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

Author keywords

Cancer therapy; Farnesyltransferase; FTI; Geranylgeranyltransferase I; GGTI; Hypothesis driven trials; Ras

Indexed keywords

1,2,3,4,9,9A HEXAHYDRO 2 [2 (2 METHOXYPHENYL) 1 OXO 2 PROPENYL] 9 (4 METHYLPHENYL) 4,9 ETHANO 3AH BENZ[F]ISOINDOLE 3A CARBOXYLIC ACID; ANTINEOPLASTIC AGENT; BENZODIAZEPINE; BMS 184878; BMS 193269; BZA 2B; CYTOTOXIC AGENT; FTI 2148; FTI 2153; GERANYLGERANYLTRANSFERASE 1 INHIBITOR; GGTI 2154; GGTI 2166; GGTI 297; GGTI 298; L 745631; LONAFARNIB; MYC PROTEIN; N (8 AMINO 2 BENZYL 5 ISOPROPYL 9 MERCAPTO 3,6 NONADIENOYL)METHIONINE; N (8 AMINO 2 BENZYL 5 ISOPROPYL 9 MERCAPTO 3,6 NONADIENOYL)METHIONINE METHYL ESTER; N [2 [2 (2 AMINO 3 MERCAPTOPROPYLAMINO) 3 METHYLPENTYLOXY] 3 PHENYLPROPIONYL]METHIONINE SULFONE; N [2 [2 (2 AMINO 3 MERCAPTOPROPYLAMINO) 3 METHYLPENTYLOXY] 3 PHENYLPROPIONYL]METHIONINE SULFONE METHYL ESTER; N [[5 [(2 AMINO 3 MERCAPTOPROPYL)AMINO][1,1' BIPHENYL] 2 YL]CARBONYL]METHIONINE; N [[5 [(2 AMINO 3 MERCAPTOPROPYL)AMINO][1,1' BIPHENYL] 2 YL]CARBONYL]METHIONINE METHYL ESTER; PLATELET DERIVED GROWTH FACTOR; PROTEIN FARNESYLTRANSFERASE INHIBITOR; PROTEIN P53; RAS PROTEIN; RHO FACTOR; TIPIFARNIB; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; CANCER; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CELL CYCLE; CHROMOSOME; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG MECHANISM; DRUG STRUCTURE; ENZYME INHIBITION; ENZYME SUBSTRATE; GENE MUTATION; HUMAN; HUMAN CELL; MITOSIS; MITOSIS SPINDLE; MOUSE; NONHUMAN; ONCOGENE H RAS; ONCOGENE K RAS; PHASE 1 CLINICAL TRIAL; PRENYLATION; QUALITY OF LIFE; REVIEW; SIGNAL TRANSDUCTION; TUMOR GROWTH;

EID: 0033652761     PISSN: 13543784     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543784.9.12.2767     Document Type: Review

References (73)

1. Protein prenylation: Molecular mechanisms and functional consequences
2. Biochemistry of protein prenylation
3. Inhibition of purified p21ras farnesyl:Protein transferase by Cys-AAX tetrapeptides
4. Ras genes
5. Human oncogenes
6. Rho family proteins and Ras transformation: The RHOad less travelled gets congested
7. Anticancer activity of farnesyltransferase and geranylgeranyltransferase I inhibitors: Prospects for drug development
8. Farnesyltransferase and geranylgeranyltransferase I inhibitors as novel agents for cancer and cardiovascular diseases
9. Farnesyltransferase inhibitors and cancer treatment: Targeting simply Ras?
10. The potential of farnesyltransferase inhibitors as cancer chemotherapeutics
11. Inhibition of Ras prenylation: A novel approach to cancer chemotherapy
12. Antitumour efficacy of a novel class of non-thiol-containing peptidomimetic inhibitors of farnesyltransferase and geranylgeranyltransferase I: Combination therapy with the cytotoxic agents cisplatin, Taxol and gemcitabine
13. Farnesyltransferase and geranylgeranyltransferase I: Targets for cancer and cardiovascular therapy
14. Disruption of oncogenic K-Ras4B processing and signaling by a potent geranylgeranyltransferase I inhibitor
15. Inhibition of the prenylation of K-Ras, but not H- Or N-Ras, is highly resistant to CAAX peptidomimetics and requires both a farnesyltransferase and a geranylgeranyltransferase I inhibitor in human tumour cell lines
16. Potent inhibition of human tumour p21ras farnesyltransferase by A1A2- Lacking p21ras CA1A2X peptidomimetics
17. Peptidomimetic inhibitors of p21ras farnesyltransferase: Hydrophobic functionalization leads to disruption of p21ras membrane association in while cells
18. Ras CAAX peptidomimetic FTI-277 selectively blocks oncogenic Ras signaling by inducing cytoplasmic accumulation of inactive Ras-Raf complexes
19. Platelet-derived growth factor receptor tyrosine phosphorylation requires protein geranylgeranylation but not farnesylation
20. Protein geranylgeranylation, not farnesylation, is required for the G1 to S phase transition in mouse fibroblasts
21. Polylysine and CVIM sequences of K-RasB dictate specificity of prenylation and confer resistance to benzodiazepine peptidomimetic in vitro
22. K- And N-Ras are geranylgeranylated in cells treated with farnesyl protein transferase inhibitors
23. Direct demonstration of geranylgeranylation and farnesylation of Ki-Ras in vivo
24. Both farnesyltransferase and geranylgeranyltransferase I inhibitors are required for inhibition of oncogenic K-Ras prenylation but each alone is sufficient to suppress human tumour growth in nude mouse xenografts
25. Ras CAAX peptidomimetic FTI 276 selectively blocks tumour growth in nude mice of a human lung carcinoma with K-Ras mutation and p53 deletion
26. Inhibition of Ras and related G-proteins as a therapeutic strategy for blocking malignant glioma growth
27. Inhibition of Ras and related guanosine triphosphate-dependent proteins as a therapeutic strategy for blocking malignant glioma growth: II-preclinical studies in a nude mouse model
28. Activation of Rac1, RhoA and mitogen-activated protein kinases is required for Ras transformation
29. A role for Rho in Ras transformation
30. Antitumour efficacy of a farnesyltransferase inhibitor in transgenic mice
31. Mouse mammary tumour virus-Ki-rasB transgenic mice develop mammary carcinomas that can be growth-inhibited by a farnesyl:protein transferase inhibitor
32. Activated Drosophila Ras1 is selectively suppressed by isoprenyl transferase inhibitors
33. Effect of farnesyltransferase inhibitor FTI-276 on established lung adenomas from A/J mice induced by 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone
34. The farnesyltransferase inhibitor FTI-277 radiosensitizes H-ras-transformed rat embryo fibroblasts
35. Inhibiting Ras prenylation increases the radiosensitivity of human tumour cell lines with activating mutations of ras oncogenes
36. A peptidomimetic inhibitor of farnesyl:Protein transferase blocks the anchorage-dependent and-independent growth of human tumour cell lines
37. Inhibition of human tumour xenograft growth by treatment with the farnesyl transferase inhibitor B956
38. Farnesyltransferase inhibition causes morphological reversion of ras- Transformed cells by a complex mechanism that involves regulation of the actin cytoskeleton
39. Ras isoforms vary in their ability to activate Raf-1 and phosphoinositide 3-kinase
40. Four human ras homologs differ in their abilities to activate Raf-1, induce transformation and stimulate cell motility
41. Farnesyltransferase inhibitors alter the prenylation and growth-stimulating function of RhoB
42. Regulation of Ras-related RhoB protein expression during the cell cycle
43. Evidence that farnesyltransferase inhibitors suppress Ras transformation by interfering with Rho activity
44. Characterization of the phosphorylation sites and the surrounding amino amino acid sequences of the p21 transforming proteins coded for by the Harvey and Kirsten strains of murine sarcoma viruses
45. Geranylgeranylated RhoB mediates suppression of human tumour cell growth by farnesyltransferase inhibitors
46. RhoB alteration is necessary for apoptotic and antineoplastic responses to farnesyltransferase inhibitors
47. Both farnesylated and geranylgeranylated RhoB inhibit malignant transformation and suppress human tumour growth in nude mice
48. Post-translational modifications of p21rho proteins
49. Farnesyl transferase inhibitors induce apoptosis of Ras-transformed cells denied substratum attachment
50. Farnesyltransferase inhibitors induce cytochrome c release and caspase 3 activation preferentially in transformed cells
51. The phosphoinositide 3-OH kinase/AKT2 pathway as a critical target for farnesyltransferase inhibitor-induced apoptosis
52. Activation of the PI3'K-AKT pathway masks the proapoptotic effects of farnesyltransferase inhibitors
53. The geranylgeranyltransferase-I inhibitor GGTI-298 arrests human tumour cells in G0/G1 and induces p21(WAF1/CIP1/SDI1) in a p53-independent manner
54. A farnesyl-protein transferase inhibitor induces p21 expression and G1 block in p53 wild type tumour cells
55. FTIs block the farnesylation of CENP-E and CENP-F and alter the association of CENP-E with the microtubules
56. The farnesyltransferase inhibitor, FTI-2153, blocks bipolar spindle formation and chromosome alignment and causes prometaphase accumulation during mitosis of human lung cancer cells
57. Specific regulation of CENP-E and kinetochores during meiosis I/meiosis II transition in pig oocytes
58. p21(WAF1/CIP1) is upregulated by the geranyl-geranyltransferase I inhibitor GGTI-298 through a transforming growth factor-β- And Sp1-responsive element: Involvement of the small GTPase rhoA
59. Signals from Ras and Rho GTPases interact to regulate expression of p21Waf1/Cip1
60. The geranylgeranyltransferase I inhibitor GGTI-298 induces hypophosphorylation of retinoblastoma and partner switching of cyclin-dependent kinase inhibitors. A potential mechanism for GGTI-298 antitumour activity
61. Phase I and pharmacokinetic study of farnesyl protein transferase inhibitor R115777 in advanced cancer
62. Phase I clinical and pharmacokinetic trial of the farnesyltransferase inhibitor R115777 on a 21-day dosing schedule
63. Use of farnesyltransferase inhibitor R155777 in relapsed and refractory acute leukemias: Preliminary results of phase I trial
64. A Phase I trial of the farnesyl transferase inhibitor SCH66336: Evidence for biological and clinical activity
65. Phase I pharmacokinetic trial of the farnesyltransferase inhibitors SCH66336 plus gemcitabine in advanced cancer
66. Phase I and pharmacologic study of continuous daily oral SCH-66336, a novel farnesyl transferase inhibitor, in patients with solid tumours
67. Pharmacokinetics and pharmacodynamics of the farnesyl protein transferase inhibitor (L-778,123) in solid tumours
68. A Phase I and pharmacologic study of the farnesyl protein transferase inhibitor L-778,123 in patients with solid cancers
69. Phase I Clinical Trial of Farnesyltransferase (FT) Inhibitor BMS-214662 in Patients with Advanced Solid Tumours
70. Early clinical experience with farnesyl protein transferase inhibitors: From the bench to the bedside
71. Phase I study of farnesyl transferase inhibitor (FTI) SCH66336 with paclitaxel in solid tumours: Dose finding, pharmacokinetics, efficacy/safety
72. Phase I trial of the farnesyl protein transferase (FPTase) inhibitor L-778123 in combination with radiotherapy
73. Phase II study of docetaxel in inoperable advanced non-small cell lung cancer